Oxford Lane Capital Corp vs uniQure N.V. Ordinary Shares — how do they compare? Oxford Lane Capital Corp trades at $8.22 (market cap $817.57M), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: uniQure N.V. Ordinary Shares is the larger of the two by market cap, and Oxford Lane Capital Corp pays a 28.78% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 51 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| OXLC | QURE | |
|---|---|---|
Market Cap | $817.57M | $1.48B |
Volume | 2,300,089 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $16.02 | $70.59 |
52-Week Low | $8.15 | $9.03 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | $1.21B | $728.62M |
Dividend Yield | 28.78% | — |
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.34, down 3.02% on the day, with a bearish technical outlook and weak earnings performance. Recent quarters show significant EPS misses, including a -$6.23 actual versus $2.26 expected in Q1 2026. The company maintains a high dividend payout of $0.20 monthly, but negative ROE and ROA highlight profitability challenges. Net asset value updates indicate substantial unrealized losses, with revenue turning negative in 2026.
The outlook is cautious due to deteriorating fundamentals and high payout ratios exceeding sustainable levels. Investment opportunities exist for yield-seeking investors attracted to the deep discount to NAV, but risks include persistent earnings volatility, reliance on financing for cash flow, and competitive pressures in the CLO space. Analyst sentiment is mixed, with 50% buy ratings offset by bearish technical signals.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →